Pharmaceuticals
China Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
China's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $1.46 Bn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $2.84 Bn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate, air pollution, and smoking. The market is segmented by drug class and by distribution channel. Some key players in this market are Sinopharm Group, Hutchison China MediTech, Zhejiang Hisun Pharmaceutical, Haisco Pharmaceutical Group, Shanghai Sine Promod Pharmaceutical, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva China Limited and others.
Buy Now
China Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Executive Summary
China's Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market was valued at $1.46 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.6% from 2022 to 2030 and will reach $2.84 Bn in 2030. In China, millions of people suffer from the common and dangerous respiratory condition known as a chronic obstructive pulmonary disease (COPD). Due to the increased prevalence of COPD and growing awareness of the condition, the COPD treatment market in China is anticipated to expand significantly over the next few years. Bronchodilators, corticosteroids, and combination therapy are the most frequently utilized COPD treatments in China.
In China, bronchodilators are the most often used COPD medication, and it is anticipated that they will hold this position throughout the prediction period. In addition to conventional medications, alternative therapies including acupuncture and herbal treatments are gaining popularity in China for the treatment of COPD. The demand for these complementary therapies is anticipated to increase as a result of the Chinese government's promotion of traditional Chinese medicine (TCM) as a treatment for COPD.
Market Dynamics
Market Growth Drivers
The prevalence of COPD in China is on the rise due to factors such as air pollution and smoking. According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease, the prevalence of COPD in China is estimated to be around 13.7%, which translates to approximately 99 Mn people. This growing prevalence of COPD is expected to drive the demand for COPD treatments in China. The elderly population in China is also growing rapidly, which is expected to increase the demand for COPD treatments. According to a report by the National Bureau of Statistics of China, the population aged 65 and above in China reached 190.64 Mn in 2020, accounting for 13.5% of the total population. This demographic trend is expected to boost the demand for COPD treatments, as the disease is more common in elderly individuals.
The Chinese government has been taking steps to improve the treatment of COPD and other respiratory diseases. For example, the government has launched several initiatives to improve air quality and reduce air pollution, which is a major risk factor for COPD. The government has also been promoting traditional Chinese medicine as a complementary treatment for COPD. These initiatives are expected to drive the demand for COPD treatments in China. There is also a growing awareness of COPD among the Chinese population, which is expected to increase the demand for COPD treatments. For example, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has been actively promoting COPD awareness in China through campaigns and educational programs. This is expected to increase the number of patients seeking treatment for COPD in China.
Market Restraints
The cost of COPD treatment in China can be a significant barrier to access for many patients. According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease, the cost of COPD treatment in China can range from $1,000 to $2,600 USD) per year. This high cost can limit access to treatment for many patients, particularly those in rural areas or with low incomes. China's healthcare system is facing challenges in meeting the growing demand for COPD treatment. According to a report by the China Health Statistical Yearbook, there were 1.55 doctors per 1,000 population in China in 2020, which is lower than in many other countries. This shortage of healthcare resources can limit access to COPD treatment, particularly in rural areas. Many patients in China may not be aware of the symptoms of COPD or the importance of seeking treatment. According to a study published in the Journal of Thoracic Disease, there is a lack of public awareness of COPD in China, with only 16.4% of respondents in a survey indicating that they had heard of the disease. This lack of patient education can result in delayed diagnosis and treatment, which can worsen the outcomes of COPD. While there are several COPD treatments available in China, some newer treatments may not be widely available.
Competitive Landscape
Key Players
- SinoPharm Group
- Hutchison China MediTech
- Zhejiang Hisun Pharmaceutical
- Haisco Pharmaceutical Group
- Shanghai Sine Promod Pharmaceutical
- AstraZeneca
- Boehringer Ingelheim Pharmaceuticals
- Novartis
- Pfizer
- Teva China Limited
Healthcare Policies and Regulatory Landscape
Healthcare policy is a critical aspect of any healthcare system, and China is no exception. The Chinese government has implemented several healthcare policies in recent years to address various challenges in the healthcare system, including those related to COPD treatment. Some of the key healthcare policies in China that impact COPD treatment include:
In 2016, the Chinese government launched the Healthy China 2030 initiative, which aims to improve the health and well-being of the Chinese population. The initiative includes several goals related to respiratory health, including reducing the incidence of COPD and improving the treatment of the disease.
The National Essential Medicines List (NEML) is a list of essential medicines that are recommended for use in the Chinese healthcare system. The NEML includes several COPD treatments, including bronchodilators and corticosteroids, which are available at lower prices to patients.
The Chinese government has been promoting traditional Chinese medicine (TCM) as a complementary treatment for COPD. In 2018, the government issued guidelines for the diagnosis and treatment of COPD with TCM, which included several TCM treatments for the disease. China has been implementing healthcare reform measures aimed at improving the accessibility and affordability of healthcare services. For example, the government has expanded health insurance coverage to more of the population and has increased funding for rural healthcare services.
Reimbursement Scenario
Reimbursement is a critical aspect of healthcare, as it helps patients access necessary treatments and medications. In China, the reimbursement scenario for COPD treatment is complex, with different reimbursement policies and systems in place for different types of treatments. Some key aspects of the reimbursement scenario for COPD treatment in China include:
China's Basic Medical Insurance system is the primary source of healthcare coverage for many Chinese citizens. Under this system, COPD treatments that are included in the National Essential Medicines List (NEML) are covered by insurance. However, the amount of coverage varies depending on the type of treatment and the insurance policy.
This insurance program is available to urban employees and their dependents. Under this system, COPD treatments that are included in the NEML are covered, but the level of coverage varies depending on the specific policy. This insurance program is available to urban residents who do not have access to the Urban Employee Basic Medical Insurance program. Under this system, COPD treatments that are included in the NEML are covered, but the level of coverage varies depending on the specific policy. This insurance program is available to rural residents. Under this system, COPD treatments that are included in the NEML are covered, but the level of coverage varies depending on the specific policy.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
China Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Segmentation
By Drug Class
Bronchodilators: Bronchodilators are medications that help to relax the muscles around the airways, making it easier to breathe. These can be further classified as short-acting or long-acting bronchodilators.
Corticosteroids: Corticosteroids are anti-inflammatory medications that can help reduce swelling and inflammation in the airways. These can be used alone or in combination with bronchodilators.
Combination therapies: Combination therapies combine bronchodilators and corticosteroids in a single medication. These are often used for patients with more severe COPD.
Phosphodiesterase-4 inhibitors: Phosphodiesterase-4 inhibitors are medications that help to reduce inflammation and improve airflow in the lungs.
Others: Other medications that may be used to treat COPD include mucolytics, oxygen therapy, and vaccines for influenza and pneumococcal disease.
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Insights10 will provide you with the reports within 10 key parameters which are:
- Market Overview
- Market Growth Drivers & Restraints
- Epidemiology of Disease Type
- Market Segmentation
- Market Share
- Competitive Landscape
- Key Company Profiles
- Healthcare Policies & Regulatory Framework
- Reimbursement Scenario
- Factors Driving Future Growth
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
(1).png)
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
- Establishing market drivers and trends
- Analyzing the regulatory landscape to understand future growth
- Market Segment based analysis to obtain revenue/volume
- Analyzing current needs and determining penetration to estimate the market
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
- Intelligent insights to take informed business decisions
- Qualitative, acute and result oriented market analysis
- Market size and forecasts from 2022 to 2030
- Opportunities for expansion and in-depth market analysis
- Segmentation and regional revenue forecasts
- Analysis of the market share and competitive landscape
- Strategic Recommendations to chart future course of action
- Comprehensive Market Research Report in PDF and PPT formats
Need more?
- Ask our analyst how this study was put together to learn more
- Discuss additional requirements as part of the free customisation
- Add more countries or regions to the scope
- Get answers to specific business questions
- Develop the business case to launch the product
- Find out how this report may influence your business revenue
Related reports (by category)
Pharmaceuticals
France Aminoglycosides Market Analysis
Pharmaceuticals
Egypt Aminoglycosides Market Analysis
Pharmaceuticals
France Diabetic Retinopathy Therapeutic Market Analysis
Related reports (by geography)
Pharmaceuticals
China Knee Cartilage Repair Market Analysis
Rare Diseases
China Hereditary Angioedema Drugs Market Analysis
Clinical Trials